Loading…

Diagnosing Dementia in the Clinical Setting: Can Amyloid PET Provide Additional Value Over Cerebrospinal Fluid?

Cerebrospinal fluid (CSF) measures of amyloid and tau are the first-line Alzheimer’s disease biomarkers in many clinical centers. We assessed if and when the addition of amyloid PET following CSF measurements provides added diagnostic value. Twenty patients from a cognitive clinic, who had undergone...

Full description

Saved in:
Bibliographic Details
Published in:Journal of Alzheimer's disease 2016-10, Vol.54 (4), p.1297-1302
Main Authors: Weston, Philip S.J., Paterson, Ross W., Dickson, John, Barnes, Anna, Bomanji, Jamshed B., Kayani, Irfan, Lunn, Michael P., Mummery, Catherine J., Warren, Jason D., Rossor, Martin N., Fox, Nick C., Zetterberg, Henrik, Schott, Jonathan M.
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Cerebrospinal fluid (CSF) measures of amyloid and tau are the first-line Alzheimer’s disease biomarkers in many clinical centers. We assessed if and when the addition of amyloid PET following CSF measurements provides added diagnostic value. Twenty patients from a cognitive clinic, who had undergone detailed assessment including CSF measures, went on to have amyloid PET. The treating neurologist’s working diagnosis, and degree of diagnostic certainty, was assessed both before and after the PET. Amyloid PET changed the diagnosis in 7/20 cases. Amyloid PET can provide added diagnostic value, particularly in young-onset, atypical dementias, where CSF results are borderline and diagnostic uncertainty remains.
ISSN:1387-2877
1875-8908
1875-8908
DOI:10.3233/JAD-160302